Searchable abstracts of presentations at key conferences in endocrinology

ea0078p64 | Thyroid | BSPED2021

Relapse of childhood Graves’ disease despite normalization of TSH Receptor Antibodies

Subramanian Sharan , Pathy Kala , Hulse Tony

Introduction: The long term remission rate of Grave’s disease in children after anti-thyroid drug (ATD) therapy is around 30% as opposed to 40-60% in adults. There still exists a controversy regarding the duration of medical treatment and the markers of long term medical remission that support cessation of therapy. Normalization of TSH Receptor Antibody (TRAb) level is considered to be a favourable marker for remission prior to stopping therapy. We report two patients who...

ea0095p10 | Bone | BSPED2023

LC–MS/MS measurements of serum zoledronate in children and young people receiving treatment – findings from the Moving Towards Individualised BisphosphonatE Therapy (TIBET) study

Bartlett Tabitha , Tang Jonathan C Y , Dunn Rachel , Subramanian Sharan , Fraser William D , Webb Emma

Background: Zoledronate is a nitrogen-containing bisphosphonate (BP) recognised for its antiresorptive potency. The pharmacokinetic/pharmacodynamic of zoledronate remains unclear. Although adverse events from overuse of BP is rare, there have been reports of over-treatment resulting in pathophysiological consequences. The current administration regimen is not tailored to the individual’s therapeutic response to zoledronate. Quantifying post-dose serum con...